Reiko Sasaki, NP
Adult Health · Los Angeles, CANPI 1891010930
Payments from drug & device makers
Across 27 payments — averaging $99.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$376
- Novo Nordisk$364
- Edwards Lifesciences$300
- Boston Scientific$250
- Medtronic$250
- AbbVie$246
- plus $891 from 8 others
What the payments were for
- Travel & lodging$50%
- Food & beverage$2,670100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $376 |
| Novo Nordisk | 3 | $364 |
| Edwards Lifesciences | 4 | $300 |
| Boston Scientific | 2 | $250 |
| Medtronic | 2 | $250 |
| AbbVie | 2 | $246 |
| Neurocrine Biosciences, Inc. | 1 | $174 |
| Silk Road Medical, Inc. | 1 | $133 |
| Sanofi-aventis U.S. LLC | 1 | $128 |
| Shield Therapeutics Inc | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| Abbott | 3 | $109 |
| Biogen | 1 | $95 |
| Averitas Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$250
- QULIPTA$246
- UBRELVY$246
- INGREZZA$174
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$156
- MINIMED 780G$152
- Edwards SAPIEN 3 Transcatheter Heart Valve$142
- ENROUTE Transcarotid Stent$133
- ENROUTE Transcarotid Neuroprotection System$133
- TZIELD$128
- RYBELSUS$125
- GENERAL PAIN MANAGEMENT$125
- ACCRUFER$124
- ZEPBOUND$121
- Ozempic$115
- AJOVY$111
How this compares
$2,677 in reported general payments places this provider in the 85th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 305 | $412,308 |
| MounjaroTirzepatide | 107 | $114,259 |
| TrulicityDulaglutide | 82 | $112,802 |
| JardianceEmpagliflozin | 69 | $78,611 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 80 | $75,064 |
| Tresiba Flextouch U-100Insulin Degludec | 97 | $61,401 |
| FarxigaDapagliflozin Propanediol | 43 | $47,019 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 80 | $38,440 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $34,467 |
| Victoza 3-PakLiraglutide | 38 | $30,072 |
| Humalog Kwikpen U-100Insulin Lispro | 75 | $25,195 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 183 | $23,832 |
| JanuviaSitagliptin Phosphate | 23 | $19,816 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 21 | $19,520 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $19,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $364 | $444,985344 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humalog Mix 75-25 | $376 | $235,246219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 785 adult health providers in California.
Other adult health in Los Angeles
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Lisa HinemanLos Angeles$29K
- Tammy HarperLos Angeles$11K
- Jennifer LettsomeLos Angeles$6K
- Melissa LeeLos Angeles$5K
- Jamie YoonLos Angeles$5K
- Siok-Hian Tay-KelleyStanford$611K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.